Clinical management of diffuse low-grade gliomas

G Lombardi, V Barresi, A Castellano, E Tabouret… - Cancers, 2020 - mdpi.com
Simple Summary Diffuse low-grade gliomas (LGG) are relatively uncommon primary brain
cancers. In recent years, the molecular, diagnostic, and therapeutic approaches have …

[HTML][HTML] ChatGPT in glioma adjuvant therapy decision making: ready to assume the role of a doctor in the tumour board?

J Haemmerli, L Sveikata, A Nouri, A May… - BMJ Health & Care …, 2023 - ncbi.nlm.nih.gov
Methods We randomly selected 10 patients with brain gliomas discussed at our institution's
central nervous system tumour board (CNS TB). Patients' clinical status, surgical outcome …

From laboratory studies to clinical trials: temozolomide use in IDH-mutant gliomas

X Sun, S Turcan - Cells, 2021 - mdpi.com
In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the
treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical …

Ferroptosis‐related gene signature as a prognostic marker for lower‐grade gliomas

Y Zheng, Q Ji, L Xie, C Wang, CN Yu… - Journal of cellular …, 2021 - Wiley Online Library
Ferroptosis is a newly discovered form of programmed cell death, which has unique
biological effects on metabolism and redox biology. In this study, the prognostic value of …

Identification and validation of an 11-ferroptosis related gene signature and its correlation with immune checkpoint molecules in glioma

Z Chen, T Wu, Z Yan, M Zhang - Frontiers in Cell and Developmental …, 2021 - frontiersin.org
Background Glioma is the most common primary malignant brain tumor with significant
mortality and morbidity. Ferroptosis, a novel form of programmed cell death (PCD), is …

The roles played by long non-coding RNAs in glioma resistance

Y Chae, J Roh, W Kim - International journal of molecular sciences, 2021 - mdpi.com
Glioma originates in the central nervous system and is classified based on both histological
features and molecular genetic characteristics. Long non-coding RNAs (lncRNAs) are …

Selumetinib: a selective MEK1 inhibitor for solid tumor treatment

M Hedayat, R Jafari, N Majidi Zolbanin - Clinical and Experimental …, 2023 - Springer
Cancer incidence is rapidly growing. Solid tumors are responsible for a majority of cancers.
Recently, molecular-targeted agents have played a significant role in cancer treatment. Ras …

Procollagen-lysine, 2-oxoglutarate 5-dioxygenase family: novel prognostic biomarkers and tumor microenvironment regulators for lower-grade glioma

S Gong, C Wu, F Köhler, J Meixensberger… - Frontiers in Cellular …, 2022 - frontiersin.org
Lower-grade glioma (LGG) is a group of tumors arising from the cells of the central nervous
system. Although various therapy interventions are used, the prognosis remains different …

Recent emerging immunological treatments for primary brain tumors: focus on chemokine-targeting immunotherapies

A Ardizzone, R Basilotta, A Filippone, L Crupi, M Lanza… - Cells, 2023 - mdpi.com
Primary brain tumors are a leading cause of death worldwide and are characterized by
extraordinary heterogeneity and high invasiveness. Current drug and radiotherapy therapies …

Early versus delayed postoperative radiotherapy for treatment of low‐grade gliomas

S Dhawan, CG Patil, C Chen… - Cochrane Database of …, 2020 - cochranelibrary.com
Early versus delayed postoperative radiotherapy for treatment of low‐grade gliomas - Dhawan,
S - 2020 | Cochrane Library Skip to Content Cookies Our site uses cookies to improve your …